Liposomal daunorubicin: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Liposomal daunorubicin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
==Overview== | ==Overview== | ||
| Line 12: | Line 12: | ||
* [http://www.thebody.com/content/art42880.html Johns Hopkins AIDS Service - New from the Food and Drug Administration (FDA)] | * [http://www.thebody.com/content/art42880.html Johns Hopkins AIDS Service - New from the Food and Drug Administration (FDA)] | ||
[[Category:Chemotherapeutic agents]] | [[Category:Chemotherapeutic agents]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 16:54, 9 August 2012
Overview
Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS-related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.
Trade name: DaunoXome®